Program
AP301 peptide
Also written as “AP301”, “AP301 Low Dose” and “Solnatide 25 mg powder for reconstitution for solution for inhalation”.
Its studies are mostly in Hyperphosphatemia · Renal Insufficiency, Chronic · Primary Graft Dysfunction · Acute Lung Injury, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Apeptico Forschung und Entwicklung | 30 open or running | phase 2since Jun 20, 2012 | Jun 20, 2012 | none ahead |
| Alebund Pharmaceuticals | 21 open or running | phase 3since Mar 19, 2025 | Mar 19, 2025 | none ahead |
| Alebund Pty | 10 open or running | phase 1since Oct 17, 2023 | Oct 17, 2023 | none ahead |
Also a collaborator on its studies: fortrea.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 20, 2012First study: phase 2 study in Acute Lung InjuryNew to Apeptico Forschung und EntwicklungApeptico Forschung und Entwicklung · NCT01627613 · 40 enrolled · Austria
- Mar 21, 2014Phase 2 study in PGD Primary Graft DysfunctionApeptico Forschung und Entwicklung · NCT02095626 · 20 enrolled · Austria
- Apr 23, 2018Phase 2 study in ARDSApeptico Forschung und Entwicklung · NCT03567577 · 92 enrolled · Austria, Germany
- Oct 17, 2023Alebund Pty's first study: phase 1 study in Healthy SubjectsNew to Alebund PtyAlebund Pty · NCT06100627 · 32 enrolled · Australia
- Mar 19, 2025Alebund Pharmaceuticals's first study: phase 3 study in HyperphosphatemiaNew to Alebund PharmaceuticalsAlebund Pharmaceuticals · NCT06933472 · 264 planned · United States, China
- Jun 5, 2025Phase 3 study in Renal Insufficiency, ChronicAlebund Pharmaceuticals · NCT07030595 · 474 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07030595Renal Insufficiency, Chronic · China | 3 | Completed | Alebund Pharmaceuticals | Oct 2, 2024 | 474 |
| NCT06933472Hyperphosphatemia · United States, China | 3 | Recruiting | Alebund Pharmaceuticals | Jun 20, 2026 | 264 |
| NCT06100627Healthy Subjects · Australia | 1 | Completed | Alebund Pty | Feb 8, 2024 | 32 |
| NCT03567577ARDS · Austria, Germany | 2 | Completed | Apeptico Forschung und Entwicklung | Dec 27, 2024 | 92 |
| NCT02095626PGD Primary Graft Dysfunction · Austria | 2 | Completed | Apeptico Forschung und Entwicklung | Mar 2015 | 20 |
| NCT01627613Acute Lung Injury · Austria | 2 | Completed | Apeptico Forschung und Entwicklung | May 2014 | 40 |
How it is read
Names in the registry
- “AP301”, 4 entries
- “AP301 Low Dose”, 2 entries
- “Solnatide 25 mg powder for reconstitution for solution for inhalation”, 1 entry
- “AP-301”, 1 entry
Conditions, from the studies’ own filings
- Hyperphosphatemia, 1 study
- Renal Insufficiency, Chronic, 1 study
- Primary Graft Dysfunction, 1 study
- Acute Lung Injury, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.